{"nctId":"NCT05263388","briefTitle":"A Trial to Compare the Ovarian Response of REKOVELLE and GONAL-F in Conventional Dosing in Women Undergoing Controlled Ovarian Stimulation","startDateStruct":{"date":"2022-07-15","type":"ACTUAL"},"conditions":["Infertility"],"count":302,"armGroups":[{"label":"REKOVELLE (Follitropin Delta)","type":"EXPERIMENTAL","interventionNames":["Drug: REKOVELLE (Follitropin Delta)"]},{"label":"GONAL-F (Follitropin Alfa)","type":"ACTIVE_COMPARATOR","interventionNames":["Other: GONAL-F (Follitropin Alfa)"]}],"interventions":[{"name":"REKOVELLE (Follitropin Delta)","otherNames":[]},{"name":"GONAL-F (Follitropin Alfa)","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Infertile women aged 18-40 years\n* Diagnosed with tubal infertility, unexplained infertility, mild endometriosis (stage I/II) or partners with decreased sperm quality\n* Medically eligible for in vitro fertilization (IVF) and/or intracytoplasmic sperm injection (ICSI)\n* Infertility for at least one year for participants ≤ 37 years or for at least 6 months for participants ≥ 38 years\n* Regular menstrual cycles of 21-35 days.\n\nExclusion Criteria:\n\n* Known condition of not functioning ovaries\n* Known advanced endometriosis (stage III/IV)\n* Considered unsuitable for controlled ovarian stimulation with a dosing regimen corresponding to approximately 225 IU/day gonadotropin, as judged by the investigator\n* History of previous episode of OHSS or exuberant ovarian response to gonadotropins, and polycystic ovarian syndrome\n* Any known hormonal or metabolic abnormalities which can compromise participation in the trial\n* Known tumors of the ovary, breast, uterus, adrenal gland, pituitary or hypothalamus","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"minimumAge":"18 Years","maximumAge":"40 Years","stdAges":["ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Oocytes Retrieved","description":"The number of oocytes retrieved was recorded at the oocyte retrieval visit.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null},{"groupId":"OG001","value":"9.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Follicles (Total) at End-of-stimulation","description":"Counted by transvaginal ultrasound for the right and left ovary for each subject.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.0","spread":null},{"groupId":"OG001","value":"12.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Size of the Follicles at End-of-stimulation","description":"Counted by ultrasound for the right and left ovary for each subject.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","spread":null},{"groupId":"OG001","value":"16.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Concentrations of Estradiol at End-of-stimulation","description":"Blood samples for analysis of circulating concentrations of estradiol were drawn.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6085.0","spread":null},{"groupId":"OG001","value":"5853.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Serum Concentrations of Progesterone at End-of-stimulation","description":"Blood samples for analysis of circulating concentrations of progesterone were drawn.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.9","spread":null},{"groupId":"OG001","value":"2.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Fertilized Oocytes","description":"The number of pronuclei were counted after insemination. Fertilized oocytes with 2 pronuclei (2PN) were regarded as correctly fertilized.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":null},{"groupId":"OG001","value":"5.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Fertilization Rate","description":"The fertilization rate was defined as the number of oocytes with 2PN divided by the number of oocytes retrieved.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.5","spread":null},{"groupId":"OG001","value":"57.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Blastocysts and Number of Good Quality Blastocysts","description":"Number of blastocysts and number of good quality blastocysts on Day 5 or 6 were presented. The quality evaluation of blastocysts consisted of assessment of three parameters, as per the Gardner \\& Schoolcraft system: blastocyst expansion and hatching status (graded: 1-6), inner cell mass (graded: A-D) and trophectoderm (graded: A-D). A good-quality blastocyst was defined as a blastocyst of grade 3BB or higher.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"2.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Gonadotropin Dose","description":"Calculated by start dates, end dates and daily dose of investigational medicinal product (IMP).","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"135","spread":null},{"groupId":"OG001","value":"148.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Stimulation Days","description":"Calculated by start dates and end dates.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.0","spread":null},{"groupId":"OG001","value":"9.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Proportion of Subjects With Early Ovarian Hyperstimulation Syndrome (OHSS) (Overall and by Grade) and/or Preventive Interventions for Early OHSS","description":"Early OHSS is defined as OHSS with onset ≤9 days after triggering of final follicular maturation. Classification of grade was according to Golan's classification system, and all OHSS cases were graded as mild, moderate or severe.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"33","spread":null},{"groupId":"OG001","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":200},"commonTop":["Headache","Pelvic pain"]}}}